Free Trial

Kepler Capital Markets' Rating of Calliditas Therapeutics AB (publ) on 6/16/2022

On June 16, 2022, Kepler Capital Markets updated its outlook on Calliditas Therapeutics AB (publ) (NASDAQ:CALT) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.